Asthma Prevalence and Control Characteristics by Race/Ethnicity -United States, 2002
During 1980-1999, asthma prevalence, morbidity, and mortality increased among U.S. adults. These annual rates were higher among certain racial/ethnic minority populations than among whites (1) . In addition, racial/ethnic minority populations reported higher use of emergency departments (EDs) and doctors' offices for asthma treatment than whites (1) . To assess asthma prevalence and asthma-control characteristics among racial/ethnic populations, CDC analyzed 2002 data from the Behavioral Risk Factor Surveillance System (BRFSS). This report summarizes the results of that analysis, which indicated that among the estimated 16 million (7.5%) U.S. adults with asthma, self-reported current asthma prevalence among racial/ethnic minority populations ranged from 3.1% to 14.5%, compared with 7.6% among whites. Comprehensive state-specific asthma surveillance data are necessary to identify disparities in asthma prevalence and asthmacontrol characteristics among racial/ethnic populations and to develop targeted public health interventions.
BRFSS is a state-based, random-digit-dialed telephone survey of the noninstitutionalized, civilian U.S. population aged >18 years. The survey collects information about modifiable risk factors for chronic diseases and other leading causes of death and is administered in English and Spanish. In 2002, two questions about asthma were used in the core survey by the 54 reporting areas (i.e., the 50 states, the District of Columbia [DC] , Guam, Puerto Rico, and the U.S. Virgin Islands [USVI]). Lifetime asthma was defined as a "yes" response to the question, "Have you ever been told by a doctor, nurse, or other health professional that you have asthma?" Current asthma was defined as a "yes" response to the same question and the question, "Do you still have asthma?" Weighted prevalence estimates and 95% confidence intervals (CIs) were calculated by using SUDAAN to account for the complex survey design. (Table 1) .
Eight questions in the Adult Asthma History Module were used in 19 areas* to examine the asthma-control characteristics among respondents with current asthma in eight racial/ ethnic populations: 1) non-Hispanic whites, 2) non-Hispanic blacks, 3) non-Hispanic Asians, 4) non-Hispanic American Indians/Alaska Natives (AI/ANs), 5) non-Hispanic Native Hawaiians/Pacific Islanders (NH/PIs), 6) non-Hispanic persons reporting "other" race/ethnicity, 7) non-Hispanic persons reporting multiple races/ethnicities, and 8) Hispanics. Respondents with current asthma were asked to report the 1) number of ED visits during the preceding 12 months, 2) number of doctors' office visits for urgent care during the preceding 12 months, 3) number of routine check-ups for asthma during the preceding 12 months, 4) presence of asthma attacks or episodes during the preceding 12 months, 5) presence of asthma symptoms during the preceding 30 days, 6) number of days with sleep disturbances during the preceding 30 days, 7) use of medication during the preceding 30 days, and 8) number of days with activity limitation during the preceding 12 months. Respondents who answered "yes" or provided a numeric response (other than zero) to any question were coded as "yes" to the question, and all other responses were coded as "no." Respondents who answered "don't know" or who refused to answer the question were excluded.
The overall current asthma prevalence in the 19 areas using the adult asthma module without race/ethnicity stratification was 7.3% (95% CI = 6.9%-7.6), compared with 7.6% for all 54 reporting areas. Current asthma prevalence in the 19 areas ranged from 4.7% (USVI) to 9.1% (DC). Current asthma was highest among non-Hispanic respondents of multiple races (15.6%), followed by non-Hispanic AI/ANs (11.6%), nonHispanic blacks (9.3%), non-Hispanic whites (7.6%), nonHispanic persons of "other" race/ethnicity (7.2%), Hispanics (5.0%), non-Hispanic Asians (2.9%), and non-Hispanic NH/ PIs (1.3%) ( Table 2 ). Hispanic respondents in Puerto Rico reported higher current asthma (11.6%) than Hispanic respondents in the 19 areas using the adult asthma module (5.0%) and Hispanic respondents in the 50 states and DC (5.5%).
Among respondents with current asthma, ED visits were reported with greater frequency by non-Hispanic black (37.2%) and Hispanic (26.0%) respondents and least frequently by non-Hispanic multiracial respondents (13.5%). Non-Hispanic white and non-Hispanic Asian respondents were the least likely to report doctors' office visits for urgent care (25.8% and 17.1%, respectively). These two racial/ethnic populations exhibited the most positive asthma-control profile, with moderate-to-low percentages of respondents reporting each of the negative indicators (i.e., ED visits, urgent care visits, symptoms, attacks, sleep disturbance, and activity limitation). Both racial/ethnic populations also reported a moderate-to-low frequency of routine doctors' visits for asthma care and medication use. Non-Hispanic black, AI/AN, multiracial, and Hispanic respondents all had less positive asthma profiles, with high percentages reporting three to five of the six negative indicators.
Editorial Note: Asthma is a chronic respiratory illness often associated with familial, allergenic, socioeconomic, psychological, and environmental factors (3) . Although recent reports suggest asthma-related mortality has been declining since 1996, a disparity remains between rates for non-Hispanic whites and those for non-Hispanic blacks and other racial/ethnic populations (4). Non-Hispanic blacks experience higher rates than non-Hispanic whites for ED visits, hospitalizations, and deaths; these trends are not explained entirely by higher asthma prevalence among non-Hispanic blacks (4) . Other racial/ethnic populations experience higher asthma mortality and hospitalization rates than non-Hispanic whites while also reporting lower asthma prevalence and fewer outpatient and ED visits. The asthma-control characteristics described in this report can contribute to increased mortality and higher hospitalization rates.
In 2002, the BRFSS adult lifetime asthma prevalence estimate and the adult current asthma prevalence estimate for the 50 states and DC were higher than in 2001 and 2000. Consistent with previous BRFSS findings, the data in this report indicate variability across states and territories in the lifetime and current asthma estimates. In addition, racial/ ethnic populations with the highest current asthma prevalence in 2001 (nonHispanics of multiple races, nonHispanic AI/ANs, and non-Hispanic blacks) reported higher adult current asthma prevalence in 2002. NonHispanic whites also reported higher adult current asthma prevalence in 2002 than in 2001. Although non-Hispanic Asians reported the lowest current asthma prevalence in 2001, current asthma prevalence decreased in 2002 in contrast to the increases reported by other racial/ethnic populations. NonHispanic NH/PIs also reported a decrease in current asthma prevalence in The findings in this report are subject to at least four limitations. First, the median response rate for the survey was 58.3%. However, BRFSS asthma prevalence is similar to estimates from other surveys with higher response rates, such as the National Health Interview Survey (5). Second, BRFSS does not measure asthma prevalence among institutionalized adults, military personnel, persons aged <18 years, and residents without telephones. Third, the validity of self-reported asthma or asthma-control characteristics in BRFSS is unknown (6) . Actual adherence to prescribed medication or asthma treatment plans in respondents with current asthma is unknown. Finally, the asthma-control questions were asked in 19 of the 54 BRFSS reporting areas and might not accurately reflect the asthma-control characteristics of other reporting areas or accurately represent their racial/ethnic distribution.
States and territories using the BRFSS Adult Asthma History module can direct asthma management within their jurisdictions and address disparities in asthma risk and control characteristics among racial/ethnic populations. Use of comprehensive state-specific asthma surveillance data to identify populations with poorly controlled asthma is instrumental in developing, implementing, and evaluating asthma-control programs and interventions. 
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Impact of a Smoking Ban on Restaurant and Bar RevenuesEl Paso, Texas, 2002
Smoke-free indoor air ordinances protect employees and customers from secondhand smoke exposure, which is associated with increased risks for heart disease and lung cancer in adults and respiratory disease in children (1,2). As of January 2004, five states (California, Connecticut, Delaware, Maine, and New York) and 72 municipalities in the United States had passed laws that prohibit smoking in almost all workplaces, restaurants, and bars (3). On January 2, 2002, El Paso, Texas (2000 population: 563,662), implemented an ordinance banning smoking in all public places and workplaces, including restaurants and bars. The El Paso smoking ban is the strongest smoke-free indoor air ordinance in Texas and includes stipulations for enforcement of the ban by firefighting and law enforcement agencies, with fines of up to $500 for ordinance violations (4) . To assess whether the El Paso smoking ban affected restaurant and bar revenues, the Texas Department of Health (TDH) and CDC analyzed sales tax and mixed-beverage tax data during the 12 years preceding and 1 year after the smoking ban was implemented. This report summarizes the results of that analysis, which determined that no statistically significant changes in restaurant and bar revenues occurred after the smoking ban took effect. These findings are consistent with those from studies of smoking bans in other U.S. cities (5) (6) (7) (8) . Local public health officials can use these data to support implementation of smokefree environments as recommended by the Task Force on Community Preventive Services (9) .
To study the impact of the El Paso smoking ban on all sectors of the local restaurant and bar industry, TDH and CDC obtained quarterly sales tax reports and monthly mixedbeverage tax receipts from the Texas Comptroller of Public Accounts. The sales tax reports provided revenue data for restaurants, bars, and retail businesses, grouped by Standardized Industrial Classification (SIC) codes. Categories were created for restaurants (SIC codes 5812, 5816, and 5817) and bars (SIC codes 5813 and 5814) (10) . The sales tax reports included revenue generated by sales of meals and sales of beer and wine for establishments with beer and wine retailer permits; sales tax revenue data were used for 1990-2002. Other restaurant and bar revenue data came from reports filed by holders of mixed-beverage permits. The state's mixedbeverage gross receipts tax, enacted in 1994, is levied on revenue generated by sales of alcoholic beverages (e.g., liquor, beer, and wine) and nonalcoholic beverages and ice used in mixed drinks. Mixed-beverage revenue data were used for 1995-2002.
Multiple linear regression analysis was used to examine the effect of the El Paso smoking ban on changes in revenue over time. The following independent variables were considered: a variable indicating whether the smoking ban was in force, an ordinal variable to represent secular time, and three variables to indicate during which one of four calendar quarters the revenue data were collected. Two regression models were created for each of the following primary dependent variables: 1) revenue subject to sales tax from all restaurants and bars, restaurants only, and bars only; and 2) revenue subject to the mixed-beverage tax. For each category, the first model examined the association between the smoking ban and revenue, and the second examined the association between the smoking ban and the fraction of revenue as a percentage of El Paso's total retail revenues (SIC codes 5211-5999). This fraction accounts for economic variation that might impact revenue in all sectors of the retail economy (6) .
Two sets of statistics were used to evaluate the quality of the models. The Durbin-Watson statistic was calculated for each model to determine if first-order autocorrelation was present. Variance inflation factors were examined to determine if multicollinearity was present in any of the models.
Restaurant, bar, and mixed-beverage revenues varied by quarter; in all categories, revenues usually were higher during the fourth quarter (October-December) of each year (Figure 1 ). During all four quarters, bar and mixed-beverage revenues accounted for approximately 1% of total retail revenues ( Figure 2) .
None of the regression models for restaurant, bar, or mixedbeverage revenues or for such revenues as percentages of total retail revenue over time showed any statistically significant changes after the smoking ban was implemented (Table) . In addition, the results did not change when revenues were adjusted for inflation, and adjusting for changes in price did not change the results (8) . In all models, the variance inflation factors had values of <2 for each of the independent variables, indicating that multicollinearity was not present, and the Durbin-Watson statistics indicated that none of the autocorrelations was statistically significant (Table) . Editorial Note: No decline in total restaurant or bar revenues occurred in El Paso, Texas, after the city's smoking ban was implemented on January 2, 2002. These findings are consistent with the results of studies in other municipalities that determined smoke-free indoor air ordinances had no effect on restaurant revenues (2, (5) (6) (7) (8) . Despite claims that these laws especially might reduce alcoholic beverage revenues (2), the mixed-beverage revenue analyses indicate that sales of alcoholic beverages were not affected by the El Paso smoking ban. The findings in this report are subject to at least three limitations. First, because sales tax reports lag revenue collection by 6 months, sales tax data were available for only 1 year after the El Paso smoking ban was implemented. However, analyses from other cities that included data for several years after a smoking ban was enacted indicated no declines in restaurant or bar revenues (6) (7) (8) . Revenue data from El Paso will be monitored for any changes in restaurant and bar revenues. Second, because limited revenue data for El Paso were available, methods that might provide better estimates of the impact of the ban could not be used. Regression models measuring changes in slope for revenues before and after implementation of smoke-free indoor air ordinances might provide better estimates of how these ordinances affect revenues (8); time-series models also might produce better estimates. When more information becomes available, these models should be applied to the El Paso data. Finally, because the SIC codebased restaurant and bar categories are not mutually exclusive, certain bars were included in the restaurant category created for this analysis. However, mixed-beverage tax data, which provide a more precise measure of alcohol-related revenue, support the finding that bar revenues were not affected by the smoking ban.
Opponents of smoke-free indoor air ordinances have claimed that enacting smoke-free indoor air ordinances will harm restaurant and bar revenues (2) . However, the findings in this report indicate that, in El Paso, Texas, restaurant and bar revenues were not affected by the smoking ban. Such analyses of 
MMWR February 27, 2004
economic data can provide local policymakers with statistical evidence to evaluate the merit of implementing smoke-free indoor air ordinances in their communities.
Effect of New Susceptibility Breakpoints on Reporting of Resistance in Streptococcus pneumoniae -United States, 2003
In January 2003, the National Committee for Clinical Laboratory Standards (NCCLS) finalized new breakpoints for defining the susceptibility of Streptococcus pneumoniae isolates to cefotaxime and ceftriaxone (1) . The former breakpoints were based on attainable concentrations of these antibiotics in cerebrospinal fluid (CSF) and the level at which it was thought that meningitis treatment failed because of elevated minimum inhibitory concentrations (MICs). The new breakpoints differ for S. pneumoniae isolates causing meningitis and those causing nonmeningeal clinical syndromes. To assess the effect of these new criteria on reporting of nonsusceptible S. pneumoniae isolates, CDC analyzed cefotaxime MIC data from the Active Bacterial Core Surveillance (ABCs) of the Emerging Infections Program (EIP) Network during 1998-2001. This report summarizes the results of that analysis, which indicated that after the new criteria were applied, the number of isolates defined as nonsusceptible to cefotaxime decreased 52.1%-61.2% for each year. Laboratory reports for clinicians should include interpretations using the new breakpoints for meningitis and nonmeningeal syndromes for all non-CSF isolates.
During (2) . A case of invasive pneumococcal disease was defined as isolation of S. pneumoniae from a normally sterile site in a resident of a surveillance area. Isolates were tested for susceptibility at reference laboratories by using NCCLS methods (1). Isolates were considered to be nonsusceptible to an antibiotic if they met intermediate or resistant criteria by MIC testing. Under the former criteria, susceptible, intermediate, and resistant MIC breakpoints for cefotaxime and ceftriaxone were <0.5, 1, and >2 µg/mL, respectively, for all pneumococci. Under the new criteria, isolates from CSF or other body sites where meningitis is suspected maintain the old breakpoints, but isolates causing nonmeningeal syndromes have breakpoints of <1, 2, and >4 µg/mL, respectively.
During 1998-2001, the number of S. pneumoniae isolates collected annually ranged from 3,128 to 3,961 (Table) . Approximately 95.6% of isolates collected caused nonmeningeal clinical syndromes such as pneumonia with bacteremia. The percentage of isolates causing meningitis ranged from 4.4% in 1998 to 5.5% in 2000.
The percentage of isolates causing nonmeningeal syndromes that were nonsusceptible to penicillin ranged from 24.3% in 1998 to 26.5% in 2000. Penicillin nonsusceptibility was consistently higher among isolates causing meningitis (Table) . The susceptibility breakpoints for penicillin remain unchanged and are the same for isolates causing both meningitis and nonmeningeal syndromes.
Under the former breakpoints, the percentage of isolates causing nonmeningeal syndromes that were nonsusceptible to cefotaxime ranged from 13.8% in 1998 to 16.7% in 2000 (Table) . Cefotaxime nonsusceptibility was consistently higher among isolates causing meningitis. When the new breakpoints were applied, the percentage of isolates causing invasive nonmeningeal syndromes defined as cefotaxime nonsusceptible decreased to 5.6%-7.4%; the percentage of isolates causing meningitis defined as nonsusceptible remained unchanged. Cefotaxime nonsusceptibility among all isolates was 6.4%-8.1%, representing a decrease of 52.1%-61.2% in cefotaxime nonsusceptibility annually (Table) . Editorial Note: When the new breakpoints were applied to previously collected ABCs MIC data for 1998-2001, the number of S. pneumoniae isolates defined as nonsusceptible to cefotaxime decreased 52.1%-61.2% each year. Although breakpoints remain unchanged for pneumococci from CSF or other body sites where meningitis is suspected, these isolates constitute only a small fraction (4%-5%) of all collected. Under the former criteria, S. pneumoniae infections treated with beta-lactam antibiotics to which isolates had intermediate resistance were associated with worse clinical outcomes for meningitis (3,4) but not for pneumonia (5) . This difference might be related to the attainable concentration level of beta-lactam antibiotics in CSF, compared with plasma and interstitial fluid. Beta-lactam antibiotic concentrations in the lung interstitia are similar to those measured simultaneously in serum, and concentrations in CSF are lower than serum levels (6) .
MIC breakpoints for penicillin were not changed because susceptibility to penicillin (MIC <0.06 µg/mL) is used to predict susceptibility to other penicillins, cephalosporins, and carbapenems. Defining new penicillin susceptibility breakpoints for nonmeningeal syndromes also would require recommending specific doses for each route of penicillin administration.
State and local health departments conduct surveillance for drug-resistant S. pneumoniae and rely on data generated by clinical laboratories. The change in susceptibility breakpoints will cause an artificial decline in the percentage of nonsusceptible S. pneumoniae isolates on surveillance reports. Health departments should examine laboratory data collected as part of surveillance programs to ensure that data are interpreted and aggregated correctly.
Antimicrobial susceptibility testing influences clinicians' antibiotic choices (7). Current recommendations for treating penicillin-resistant pneumococcal pneumonia suggest choosing one of the following agents on the basis of susceptibility testing results: cefotaxime, ceftriaxone, selected fluoroquinolones, or, if the isolate is resistant to fluoroquinolone and cephalosporin, vancomycin (8) . New clinical-syndromebased susceptibility breakpoints for cefotaxime and ceftriaxone might lead to an increase in use of these antibiotics to treat nonmeningeal pneumococcal disease over broader-spectrum antibiotics (e.g., fluoroquinolones). S. pneumoniae strains resistant to fluoroquinolones are uncommon, but development of resistance is a concern (9) . If the new NCCLS susceptibility breakpoints promote using narrower-spectrum antibiotics to treat pneumococcal disease, development of resistance to broader-spectrum antibiotics might be slowed.
Interim Guidelines for the Evaluation of Infants Born to Mothers Infected with West Nile Virus During Pregnancy
West Nile virus (WNV) is a single-stranded RNA flavivirus with antigenic similarities to Japanese encephalitis and St. Louis encephalitis viruses. It is transmitted to humans primarily through the bites of infected mosquitoes. Flavivirus infection during pregnancy has been associated rarely with both spontaneous abortion and neonatal illness but has not been known to cause birth defects in humans (1-4) . During 2002, a total of 4,156 cases of WNV illness in humans, including 2,946 cases of neuroinvasive disease, were reported to CDC by state health departments. In 2002, a woman who had WNV encephalitis during the 27th week of her pregnancy delivered a full-term infant with chorioretinitis, cystic destruction of cerebral tissue, and laboratory evidence of congenitally acquired WNV infection (5, 6) . Although this case demonstrated intrauterine WNV infection in an infant with congenital abnormalities, it did not prove a causal relation between WNV infection and these abnormalities. During 2002, CDC investigated three other instances of maternal WNV infection. In all three cases, the infants were born at full term with normal appearance and negative laboratory tests for WNV infection; cranial imaging studies and ophthalmologic examinations were not performed. During 2003, CDC received reports of approximately 9,100 cases of WNV illness, including approximately 2,600 cases of neuroinvasive disease*. CDC is gathering data on pregnancy outcomes for approximately 70 women with WNV illness during pregnancy (CDC, unpublished data, 2003).
To develop guidelines for evaluating infants born to mothers who acquire WNV infection during pregnancy, on December 2, 2003, CDC convened a meeting of specialists in the evaluation of congenital infections. This report summarizes the interim guidelines established during that meeting.
Screening for WNV During Pregnancy
No specific treatment for WNV infection exists, and the consequences of WNV infection during pregnancy have not been well defined. For these reasons, screening of asymptomatic pregnant women for WNV infection is not recommended.
Diagnosis of WNV Infection During Pregnancy
Pregnant women who have meningitis, encephalitis, acute flaccid paralysis, or unexplained fever in an area of ongoing WNV transmission should have serum (and cerebrospinal fluid [CSF] , if clinically indicated) tested for antibody to WNV. If serologic or other laboratory tests indicate recent infection with WNV, these infections should be reported to the local or state health department, and the women should be followed to determine the outcomes of their pregnancies.
Evaluation of the Fetus in Pregnant Women with WNV Infection
If WNV illness is diagnosed during pregnancy, a detailed ultrasound examination of the fetus to evaluate for structural abnormalities should be considered no sooner than 2-4 weeks after onset of WNV illness in the mother, unless earlier examination is otherwise indicated. Amniotic fluid, chorionic villi, or fetal serum can be tested for evidence of WNV infection. However, the sensitivity, specificity, and predictive value of tests that might be used to evaluate fetal WNV infection are not known, and the clinical consequences of fetal infection have not been determined. In case of miscarriage or induced abortion, testing of all products of conception (e.g., the placenta and umbilical cord) for evidence of WNV infection is advised to document the effects of WNV infection on pregnancy outcome.
Evaluation of Infants Born to Mothers Infected with WNV During Pregnancy
When an infant is born to a mother who was known or suspected to have WNV infection during pregnancy, clinical evaluation is recommended (Box 1). Further evaluation should be considered if any clinical abnormality is identified or if laboratory testing indicates that an infant might have congenital WNV infection (Box 2). 
BOX 1. Recommended clinical evaluation of infants born to mothers infected with West Nile virus (WNV) during pregnancy
• Thorough physical examination, including careful measurement of the head circumference, length, weight, and assessment of gestational age.
• Evaluation for neurologic abnormalities, dysmorphic features, splenomegaly, hepatomegaly, and rash or other skin lesions. Any rash, skin lesions, or dysmorphic features should be photographed. If an abnormality is noted, consultation with an appropriate specialist is recommended.
• Testing of infant serum for IgM and IgG antibody to
WNV. The initial sample should be collected either from the umbilical cord or directly from the infant within 2 days of birth. If maternal WNV illness occurred <8 days before delivery and the initial infant serum sample is negative for WNV IgM antibody, a second infant serum sample should be obtained >2 weeks after the first sample. Free testing of samples by CDC can be arranged by contacting state public health laboratories.
• Evaluation of hearing by evoked otoacoustic emissions testing or auditory brainstem response testing, either before discharge from the hospital or within 1 month after birth. Infants with abnormal initial hearing screens should be referred to an audiologist for further evaluation.
• Initial examination of the placenta by a pathologist is encouraged. Regardless of whether this is completed, the entire placenta, a sample of umbilical cord tissue, and a sample of serum from the umbilical cord should be retained for further evaluation if congenital WNV infection is identified or strongly suspected. A section of the placenta and umbilical cord should be frozen, and the remainder of the placenta should be preserved in formalin; a sample of umbilical cord blood should be centrifuged, and the serum should be refrigerated or frozen.
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Prevention of WNV Infection During Pregnancy
Pregnant women who live in areas with WNV-infected mosquitoes should apply insect repellent to skin and clothes when exposed to mosquitoes and wear clothing that will help protect against mosquito bites. In addition, whenever possible, pregnant women should avoid being outdoors during peak mosquito-feeding times (i.e., usually dawn and dusk). 
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